DEVELOPMENT OF PEDAGOGICAL TECHNOLOGIES IN
MODERN SCIENCES
International scientific-online conference
141
THE ROLE OF MODERN BIOMARKERS IN DIAGNOSING ANEMIA
AND THEIR APPLICATION IN UZBEKISTAN
Ulug'boyeva Odina
University of Business and Science, Department
of Therapeutic Work
24_05 group students
Usmonova Feruza Nematjonovna
Scientific advisor:
https://doi.org/10.5281/zenodo.15488766
Abstract:
Anemia remains a significant global health challenge, particularly
in resource-constrained settings like Uzbekistan, where its multifactorial
etiology complicates diagnosis and management. Modern biomarkers, including
hepcidin, soluble transferrin receptor (sTfR), reticulocyte hemoglobin content
(CHr), erythroferrone, and growth differentiation factor 15 (GDF-15), have
transformed anemia diagnostics by offering superior specificity and sensitivity
over conventional markers such as hemoglobin and ferritin. These biomarkers
enable precise differentiation of anemia subtypes, including iron deficiency
anemia (IDA), anemia of chronic disease (ACD), and hemolytic anemias,
facilitating targeted therapeutic interventions. This article comprehensively
explores the diagnostic utility of these biomarkers, their integration into clinical
practice, and the practical challenges and opportunities for their implementation
in Uzbekistan, considering the country’s healthcare infrastructure, economic
limitations, and unique epidemiological profile. By bridging global diagnostic
advancements with local needs, this study highlights the transformative
potential of biomarkers in enhancing anemia management in Uzbekistan.
Keywords:
Anemia, biomarkers, hepcidin, soluble transferrin receptor,
reticulocyte hemoglobin content, erythroferrone, growth differentiation factor
15, Uzbekistan, iron deficiency anemia, diagnostic precision
Anemia, defined by a decrease in red blood cell mass or hemoglobin
concentration, affects over 1.9 billion people worldwide, with disproportionate
prevalence in low- and middle-income countries. In Uzbekistan, anemia is a
pressing public health issue, particularly among women of reproductive age,
children, and the elderly, driven by nutritional deficiencies, chronic infections,
and genetic hemoglobinopathies. Traditional diagnostic tools, such as
hemoglobin measurement, serum ferritin, and peripheral blood smears, often
fail to distinguish between anemia subtypes due to overlapping clinical features
and the influence of confounding factors like inflammation. The emergence of
modern biomarkers has revolutionized anemia diagnostics by providing
DEVELOPMENT OF PEDAGOGICAL TECHNOLOGIES IN
MODERN SCIENCES
International scientific-online conference
142
detailed insights into iron metabolism, erythropoiesis, and underlying
pathophysiological processes. This article examines the role of key
biomarkers—hepcidin, soluble transferrin receptor (sTfR), reticulocyte
hemoglobin content (CHr), erythroferrone, and growth differentiation factor 15
(GDF-15)—in improving diagnostic accuracy and evaluates their feasibility for
widespread adoption in Uzbekistan’s healthcare system, considering
infrastructural, economic, and epidemiological factors.
Hepcidin, a liver-derived peptide hormone, is a master regulator of iron
homeostasis, controlling iron absorption and mobilization by degrading
ferroportin, the primary iron exporter. In iron deficiency anemia (IDA), low
hepcidin levels enhance intestinal iron uptake and macrophage iron release to
meet erythropoietic demands. Conversely, in anemia of chronic disease (ACD),
elevated hepcidin levels, driven by inflammatory cytokines like interleukin-6,
sequester iron in storage sites, limiting its availability for red blood cell
production. Hepcidin measurement, typically via enzyme-linked immunosorbent
assays (ELISA) or liquid chromatography-mass spectrometry (LC-MS), enables
precise differentiation between IDA and ACD, guiding therapeutic decisions such
as iron supplementation or anti-inflammatory treatments. However, hepcidin’s
clinical utility is complicated by its sensitivity to inflammation, renal function,
and diurnal fluctuations, necessitating standardized sampling protocols and
population-specific reference ranges.
Soluble transferrin receptor (sTfR) is a biomarker of erythropoietic activity
and iron status, expressed on erythroid precursors and shed into the
bloodstream. Unlike ferritin, sTfR is minimally affected by inflammation, making
it an ideal marker for detecting iron deficiency in patients with chronic
inflammatory conditions, such as tuberculosis or rheumatoid arthritis, which are
prevalent in Uzbekistan. Elevated sTfR levels indicate increased erythroid
demand, as seen in IDA or hemolytic anemias, while normal levels are
characteristic of ACD. The sTfR/log ferritin index enhances diagnostic specificity
by integrating iron stores and erythropoietic activity, offering a robust tool for
complex cases. Automated immunoassays for sTfR are standard in high-income
countries, but their high cost and requirement for specialized equipment limit
their use in Uzbekistan, particularly in rural healthcare facilities.
Reticulocyte hemoglobin content (CHr) measures the hemoglobin content
of newly formed red blood cells, providing an early indicator of iron availability
for erythropoiesis. CHr is particularly valuable for detecting functional iron
deficiency in patients undergoing erythropoiesis-stimulating agent therapy or
DEVELOPMENT OF PEDAGOGICAL TECHNOLOGIES IN
MODERN SCIENCES
International scientific-online conference
143
those with chronic kidney disease, both of which are increasing in Uzbekistan
due to rising non-communicable disease burdens. A CHr value below 28 pg
strongly suggests IDA, while normal or elevated values may indicate other
anemia etiologies, such as megaloblastic anemia or hemolysis. CHr is measured
using advanced hematology analyzers, which are available in major hospitals in
Tashkent and Samarkand but scarce in peripheral regions, highlighting
disparities in diagnostic capacity.
Erythroferrone, a recently identified biomarker, is an erythroid regulator of
iron metabolism, suppressing hepcidin production in response to increased
erythropoiesis. Elevated erythroferrone levels are observed in conditions with
high erythroid activity, such as thalassemia or hemolytic anemias, which are
relevant in Uzbekistan due to the prevalence of hemoglobinopathies in certain
ethnic groups. By modulating hepcidin, erythroferrone provides insights into the
balance between erythropoiesis and iron availability, offering a complementary
diagnostic tool for complex anemias. However, erythroferrone assays are
primarily research-based, with limited commercial availability, posing
significant barriers to clinical adoption in resource-limited settings.
Growth differentiation factor 15 (GDF-15), a stress-responsive cytokine, is
elevated in conditions associated with ineffective erythropoiesis, such as
thalassemia, sickle cell disease, and myelodysplastic syndromes. GDF-15
suppresses hepcidin expression, contributing to iron overload in these
disorders. Measuring GDF-15 levels, typically via ELISA, can aid in identifying
anemias with underlying bone marrow dysfunction, which are often
underdiagnosed in Uzbekistan due to limited access to bone marrow aspiration
and genetic testing. The integration of GDF-15 with other biomarkers, such as
hepcidin and erythroferrone, enhances diagnostic algorithms for rare and
hereditary anemias, but its high assay costs and lack of standardized cutoffs
limit its routine use.
The application of these biomarkers in Uzbekistan is shaped by a complex
interplay of healthcare infrastructure, economic constraints, and
epidemiological patterns. Uzbekistan has made significant progress in
strengthening its healthcare system, with investments in diagnostic laboratories,
medical education, and universal health coverage initiatives. However,
disparities between urban and rural healthcare access remain stark, with
advanced diagnostic tools concentrated in major cities like Tashkent, Bukhara,
and Samarkand. For instance, while hemoglobin testing is nearly ubiquitous,
specialized assays for hepcidin, sTfR, or erythroferrone are available only in
DEVELOPMENT OF PEDAGOGICAL TECHNOLOGIES IN
MODERN SCIENCES
International scientific-online conference
144
select research institutes or private clinics, often at prohibitive costs for the
average patient. The reliance on outdated diagnostic methods, such as manual
blood smears, in rural clinics further exacerbates diagnostic delays and
misdiagnoses.
Economic barriers significantly hinder biomarker adoption. The cost of
ELISA kits, LC-MS systems, or advanced hematology analyzers is substantial, and
public healthcare budgets in Uzbekistan prioritize essential services over
cutting-edge diagnostics. Limited reimbursement policies for specialized tests
mean that patients often bear out-of-pocket costs, which is unsustainable given
the country’s average income levels. Additionally, the lack of locally validated
reference ranges for biomarkers complicates their interpretation, as genetic
polymorphisms, dietary habits (e.g., low meat consumption), and environmental
factors in Central Asia may alter baseline values. For example, studies suggest
that Uzbek populations may have distinct iron metabolism profiles due to high
prevalence of parasitic infections and micronutrient deficiencies, necessitating
tailored diagnostic thresholds.
Epidemiologically, Uzbekistan faces a diverse anemia burden. Iron
deficiency anemia, driven by inadequate dietary iron, parasitic infections, and
frequent pregnancies, remains the most common form, particularly in rural
areas. However, the rising incidence of chronic diseases, including diabetes,
cardiovascular disorders, and chronic kidney disease, has increased the
prevalence of ACD, requiring biomarkers like sTfR to differentiate it from IDA.
Genetic anemias, such as beta-thalassemia and glucose-6-phosphate
dehydrogenase deficiency, are significant in regions like Fergana and Khorezm,
where consanguineous marriages are more common. Biomarkers like
erythroferrone and GDF-15 are critical for diagnosing these conditions, but their
limited availability underscores the need for targeted screening programs.
Furthermore, the high burden of infectious diseases, including tuberculosis and
hepatitis, complicates anemia diagnosis, as inflammation alters traditional
marker levels, reinforcing the value of inflammation-independent biomarkers
like sTfR and CHr.
Opportunities to integrate modern biomarkers into Uzbekistan’s healthcare
system are substantial, despite the challenges. Public-private partnerships could
subsidize the procurement of diagnostic equipment, while international
collaborations with organizations like the World Health Organization could
support capacity-building for laboratory technicians. Mobile diagnostic units,
equipped with portable hematology analyzers, could bridge the urban-rural
DEVELOPMENT OF PEDAGOGICAL TECHNOLOGIES IN
MODERN SCIENCES
International scientific-online conference
145
divide, enabling CHr and hemoglobin testing in remote areas. Incorporating
biomarker testing into national health programs, such as those targeting
maternal and child health, could prioritize early anemia detection, reducing
complications like maternal mortality and developmental delays in children.
Additionally, regional research initiatives could validate biomarker reference
ranges, leveraging Uzbekistan’s growing academic infrastructure, including
institutions like the Tashkent Medical Academy.
Technological advancements offer further promise. Point-of-care (POC)
testing platforms, which are portable and cost-effective, could democratize
access to biomarkers like sTfR and hepcidin. For example, microfluidic devices
and lateral flow assays, currently under development globally, could enable
rapid biomarker testing in primary care settings, aligning with Uzbekistan’s
push for decentralized healthcare. Telemedicine, increasingly adopted in
Uzbekistan, could facilitate remote consultation with specialists for interpreting
complex biomarker profiles, improving diagnostic accuracy in underserved
areas. Moreover, integrating biomarker data with electronic health records, a
priority in Uzbekistan’s healthcare digitization efforts, could streamline anemia
management and enable longitudinal monitoring of at-risk populations.
In conclusion, modern biomarkers—hepcidin, sTfR, CHr, erythroferrone,
and GDF-15—represent a paradigm shift in anemia diagnostics, offering
unparalleled precision in identifying anemia subtypes and guiding therapy.
Their implementation in Uzbekistan, while hindered by economic,
infrastructural, and epidemiological challenges, is achievable through strategic
investments in technology, training, and research. By aligning biomarker use
with local disease patterns and healthcare priorities, Uzbekistan can enhance
anemia diagnosis and management, reducing its public health burden and
improving quality of life for millions. Future efforts should focus on developing
cost-effective diagnostic platforms, validating population-specific reference
ranges, and integrating biomarkers into national health strategies to ensure
equitable access and sustainable impact.
References:
1. Abdullaev, A. K., & Karimova, N. M. (2020). Prevalence and diagnosis of
anemia in Uzbekistan. Tashkent: Uzbekistan Medical Journal, 15(3), 45-52.
2. Rakhimov, S. T. (2022). New approaches to the treatment of iron deficiency
anemia. Samarkand: Samarkand State Medical Institute Scientific Bulletin, 10(2),
78-85.
3. World Health Organization. (2021). Global anemia reduction efforts: Progress
and challenges. Geneva: WHO Press.
DEVELOPMENT OF PEDAGOGICAL TECHNOLOGIES IN
MODERN SCIENCES
International scientific-online conference
146
4. Kassebaum, N. J., & GBD 2013 Anemia Collaborators. (2016). The global
burden of anemia. Hematology/Oncology Clinics of North America, 30(2), 247-
308.
5. Nemeth, E., & Ganz, T. (2014). Hepcidin and iron homeostasis. Annual Review
of Medicine, 65, 147-158.
6. Camaschella, C., & Pagani, A. (2018). Advances in understanding iron
metabolism and anemia. Blood, 131(1), 51-58.
